Digest Network Come funziona
Network
/
Società
Al
Non verificato

Aldeyra Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOtticaSalute

28 comunicati stampa

Guarda tutti i comunicati
13/11/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Web e Social Network
Telefonia e Varie
Industria
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/11/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Finanza
Eventi
Industria
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Finanza
Web e Social Network
Oncologia
Salute
Scienza
Farmaceutica
Ottica
Biotecnologia
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/10/2025
Multimedialità
Industria
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
Medicina - Varie
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
03/09/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Web e Social Network
Eventi
Industria
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
28/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Industria
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
19/08/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Ottica
Industria
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
06/08/2025
Biotecnologia
Farmaceutica
Ottica
Salute
Eventi
Web e Social Network
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
24/07/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0
17/07/2025
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
Igiene alimentare
Medicina - Varie
Industria
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Fonte
Aldeyra Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0